To the Editor: On the basis of previous observational findings, 1 the TRUST trial was initiated to provide evidence as to whether subclinical hypothyroidism is causally linked to disease in old age. Despite being the largest trial to date with 737 participants, it was underpowered to address the association between hypothyroidism and cardiovascular disease, as highlighted in the Discussion section.
We conducted a two-sample mendelian randomization study with 20 genetic variants for circulating levels of thyrotropin and 3 genetic variants for circulating levels of free thyroxine 2 on summary data of a genomewide association study consisting of 60,801 case patients with coronary artery disease and 123,504 controls from the CARDIoGRAMplusC4D Consortium. 3 On the basis of statistical analyses that have been described previously, 4 we found no evidence for a causal relationship between circulating levels of thyrotropin or free thyroxine and the risk of coronary artery disease (odds ratio of 0.99 per standard deviation of increase in thyrotropin, P = 0.83; and odds ratio of 1.02 per standard deviation of increase in free thyroxine, P = 0.74). Thus, even if the TRUST trial had been considerably larger and had longer follow-up, it is likely that the investigators would have found no beneficial effect of levothyroxine treatment on the incidence of coronary artery disease, similar to their findings with respect to other outcomes.
To the Editor: Subclinical hypothyroidism is a common biochemical diagnosis, defined as increased levels of serum thyrotropin with normal levels of serum free thyroxine. The use of the commonly employed direct immunoassay to measure thyrotropin and free thyroxine has some major limitations. 1 Such limitations are particularly due to changes in binding protein concentrations that occur in many physiologic and disease states and a weak inverse linear log relationship to thyrotropin in thyroid disorders, factors that frequently do not fit in with the clinical presentation. 2 The measurements of free thyroxine and free triiodothyronine followed by liquid chromatography-mass spectrometry are the most clinically relevant for the evaluation of thyroid disorders and can be achieved with the use of equilibrium dialysis or ultrafiltration to measure the free thyroid concentrations. 3 In one study, approximately two thirds of the patients with subclinical hypothyroidism (as ascertained by means of immunoassays) were found to have true hypothyroidism when these definitive mass spectrometric methods were used. 4 Liquid chromatography-mass spectrometry assays are highly specific, sensitive, and precise and can detect hormones found in low concentrations, with a higher and more accurate correlation coefficient between free thyroxine and the log-transformed thyrotropin level than that obtained on immunoassays. 5 The use of such assays can avoid the misclassification of thyroid disorders, which could have an effect on the care of patients and on research. 
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To the Editor: Stott et al. conclude that levothyroxine provided no apparent benefits in older persons with subclinical hypothyroidism. However, even high-normal levels of thyrotropin (>2.5 mIU per liter) are associated with metabolic risk factors. 1 Moreover, geriatric patients are typically taking multiple drugs. The intake of levothyroxine too close to the consumption of food or drink can cause relevant fluctuations in the results on thyroid-function testing. 2, 3 Such fluctuations can result in on-and-off overreplacement, with clinical symptoms of thyrotoxicosis that may have obscured the beneficial effects of levothyroxine replacement. The trial protocol mentions that levothyroxine was prescribed to be taken "before breakfast" without further specification of the precise timing of administration. We have implemented an update in the recent versions of the British National Formula suggesting that levothyroxine should be taken at least 30 minutes before breakfast and the intake of caffeine-containing beverages to facilitate more reliable absorption, a recommendation that is in line with those of other countries, including the United States. 4 Outcomes of the trial by Stott et al. might have been different if the investigators had made more specific recommendations regarding the precise timing of levothyroxine intake, with possibly important implications for the treatment The authors reply: Ogunsakin et al. ask for post-treatment free thyroxine values. Although we did not measure such levels routinely, we did report levels in a subsample of the participants, in whom levels of free thyroxine were 2.3 pmol per liter higher in the levothyroxine group than in the placebo group (Table S2 in the Supplementary Appendix of our article, available with the full text at NEJM.org). We agree that lipid levels in our trial will be of great interest. The results of such assays will be included as part of our portfolio of work on the trial biobank.
Ogunsakin et al. note an imbalance between the levothyroxine group and the placebo group in the point estimates for cardiovascular deaths and deaths from any cause. There was 1 cardiovascular death plus 4 noncardiovascular deaths in the placebo group (during 577.9 person-years of follow-up) as compared with 2 and 8, respectively, in the levothyroxine group (during 586.9 person-years of follow-up). The confidence intervals for the treatment effect are very wide (hazard ratio for death from any cause, 1.91; 95% confidence interval, 0.65 to 5.60), so it is currently not possible to state whether levothyroxine treatment might be harmful to or indeed beneficial for these outcomes.
We agree with van Vliet et al. that our trial was underpowered to determine whether treatment of subclinical hypothyroidism with levothyroxine reduces the risk of cardiovascular disease. Mendelian randomization studies can provide useful information to help determine whether epidemiologic associations are potentially causal, and we note the finding of their research with interest. All the measures of thyrotropin and free thyroxine in our trial were determined by means of immunoassay with the use of established methods. Although analyses of thyrotropin on immunoassay platforms are considered to be reliable, the validity of immunoassay measures of free thyroxine has been questioned. 1 The hypothesis of Hannah-Shmouni and Soldin -that the use of equilibrium dialysis or ultrafiltration assays to identify patients with low free thyroxine levels might help in identifying those who would benefit from levothyroxine treatment -is interesting but remains to be proven. We hope to address this issue as part of our work on the trial biobank.
